Rosiglitazone + Metformin

Thông tin thuốc gốc
Chỉ định và Liều dùng
Type 2 diabetes mellitus
Adult: Each tab contains rosiglitazone (mg)/metformin (mg): 2/500, 4/500, 2/1,000, 4/1,000: Patients inadequately controlled on diet and exercise: Initially, 2 mg/500 mg 1-2 times daily. Patients w/ HbA1c >11% or fasting plasma glucose (FPG) >270 mg/dL: 2 mg/500 mg bid. Adjust daily dose in increments of 2 mg/500 mg in divided doses if not adequately controlled after 4 wk. Patients inadequately controlled on metformin monotherapy: Initially, rosiglitazone 4 mg daily plus the current dose of metformin. Patients inadequately controlled on rosiglitazone monotherapy: Initially, metformin 1,000 mg daily plus the current dose of rosiglitazone. Adjust daily dose in increments of rosiglitazone 4 mg if not adequately controlled after 8-12 wk and/or metformin 500 mg if not adequately controlled after 1-2 wk. Max: Rosiglitazone 8 mg and metformin 2,000 mg daily.
Suy thận
CrCl (mL/min) Dosage
<60 Contraindicated.
Suy gan
Severe: Contraindicated.
Cách dùng
Should be taken with food.
Chống chỉ định
Patient w/ established New York Heart Association (NHYA) class I to IV heart failure; acute or chronic metabolic acidosis, including diabetic ketoacidosis; type 1 DM. Conditions that may increase the risk of lactic acidosis (e.g. CV disease, acute coronary syndrome, conditions associated w/ tissue hypoxia, pulmonary embolism, pancreatitis). Excessive alcohol use. Renal (CrCl <60 mL/min) or severe hepatic impairment. Concomitant use w/ insulin and admin of IV iodinated contrast materials.
Thận trọng
Patient w/ oedema, fracture risk factors, anaemia or depressed leukocyte counts. Mild to moderate hepatic impairment. Pregnancy and lactation.
Tác dụng không mong muốn
Oedema, wt gain, anaemia, bone fracture, nausea and vomiting, diarrhoea, headache, dyspepsia, macular oedema, decreased Hb and haematocrit, decreased vit B12 serum levels, ovulation (in premenopausal anovulatory women).
Potentially Fatal: Lactic acidosis, CHF, MI.
Chỉ số theo dõi
Monitor for signs/symptoms of oedema or heart failure; renal function, BP, liver enzymes, fasting blood glucose and HbA1c. Regular ophth examination.
Quá liều
Symptoms: Lactic acidosis may occur from metformin overdose. Management: Supportive treatment.
Tương tác
Increased plasma levels w/ CYP2C8 inhibitors (e.g. gemfibrozil). Decreased plasma levels w/ CYP2C8 inducers (e.g. rifampicin).
Potentially Fatal: Increased risk of CHF w/ insulin. Alteration of renal function w/ iodinated contrast materials.
Tương tác với thức ăn
Alcohol may increase the risk of lactic acidosis, avoid use.
Tác dụng
Description: Rosiglitazone lowers blood glucose by improving target cell response to insulin in adipose tissue, skeletal muscle and liver, w/o increasing pancreatic insulin secretion. Metformin improves glucose tolerance in patients w/ type 2 DM, lowering both basal and post-prandial blood glucose. It decreases hepatic gluconeogenesis, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilisation.
Absorption: Rosiglitazone: Well absorbed from the GI tract. Bioavailability: 99%. Time to peak plasma concentration: Approx 1 hr. Metformin: Slowly and incompletely absorbed from the GI tract. Bioavailability: Approx 50-60%.
Distribution: Rosiglitazone: Crosses the placenta and found in foetal tissue. Plasma protein binding: Approx 99.8%. Metformin: Crosses the placenta and enters breast milk (small amounts).
Metabolism: Rosiglitazone: Extensively metabolised, mainly by CYP2C8 isoenzyme. Metformin: Not metabolised in the liver.
Excretion: Rosiglitazone: Via urine and faeces. Half-life: 3-4 hr. Metformin: Via urine (as unchanged drug). Elimination half-life: Approx 2-6 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Rosiglitazone, CID=77999, (accessed on Jan. 23, 2020)

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Metformin, CID=4091, (accessed on Jan. 20, 2020)

Bảo quản
Store at 25°C. Protect from light.
Phân loại MIMS
Thuốc trị đái tháo đường
Phân loại ATC
A10BD03 - metformin and rosiglitazone ; Belongs to the class of combinations of oral blood glucose lowering drugs. Used in the treatment of diabetes.
Tài liệu tham khảo
Anon. Rosiglitazone and Metformin. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 19/10/2015.

Avandamet Tablet, Film Coated (GlaxoSmithKline LLC). DailyMed. Source: U.S. National Library of Medicine. Accessed 19/10/2015.

Buckingham R (ed). Metformin Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 20/10/2015.

Buckingham R (ed). Rosiglitazone. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 20/10/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Rosiglitazone + Metformin từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2022 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Avahasan
  • Avandamet
  • Doromet
  • Rogelin
  • Rosfase-M
  • Rosiglen MF
  • SAVI Metformin Plus
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in